Cardiff Oncology (CRDF) Q3 2024 Earnings
CRDF·Reported November 7, 2024·Before market open
Cardiff Oncology reported Q3 2024 revenue of $165.0K, beat analyst consensus of $70.0K by $95.0K. Diluted EPS came in at $-0.25, beat the $-0.27 consensus by $0.02.
Revenue
$165.0Kbeat by $95.0K
Consensus: $70.0KDiluted EPS
$-0.25beat by $0.02
Consensus: $-0.27
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Cardiff Oncology's Q3 2024 earnings report.
Cardiff Oncology (CRDF) reported Q3 2024 earnings on November 7, 2024 before market open.
Cardiff Oncology reported revenue of $165.0K and diluted EPS of $-0.25 for Q3 2024.
Revenue beat the consensus estimate of $70.0K by $95.0K. EPS beat the consensus estimate of $-0.27 by $0.02.
You can read the 10-Q periodic report (0000950170-24-123242) directly on SEC EDGAR. The filing index links above go to sec.gov.